PerkinElmer to acquire Nexcelom for $260M

By The Science Advisory Board staff writers

May 13, 2021 -- PerkinElmer has entered into an agreement to acquire life sciences instrumentation firm Nexcelom Bioscience for $260 million, a deal that is expected to be completed in the second quarter of 2021.

Nexcelom is a provider of automated cell counting instruments, image cytometry workstations, assays, and a variety of cell reagents and consumables. It also provides fit-for-purpose cell counting method selection and development services to support cell and gene and immuno-oncology therapies, virology drugs, and vaccine development.

Nexcelom's technology portfolio will complement PerkinElmer's existing capabilities, including high content, in vivo, and cell painting screening technologies; immunoassays; CRISPR, RNA interference (RNAi), and DNA tools and custom cell lines; cell plate readers and advanced automation; and microfluidics and analytical platforms, the firms said.

PerkinElmer posts major gains in Q1
PerkinElmer reported sharp increases in revenues and net income for the first quarter of 2021.
PerkinElmer contributes to PROTACs research
PerkinElmer is serving as a provider and co-developer of assays, instruments, and expertise for the ProxiDrugs Consortium, which is zeroing in on research...
PerkinElmer, Insightful Science to integrate software with cloud-based data
PerkinElmer has inked a collaboration with Insightful Science through which it will expand its documentation, workflow, and decision-making Signals informatics...
COVID-19 concerns may undermine vaccine rates for seasonal flu
COVID-19 concerns may undermine vaccine rates for seasonal flu

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter